GSK Has 25 Potential Launches By Decade’s End; Neuroscience A Focus
Executive Summary
GlaxoSmithKline could see 25 new drug launches in the time period from 2007 to 2009, including 12 new chemical entities, eight product line extensions and five vaccines, R&D Chairman Moncef Slaoui stated during a pipeline update with investors Dec. 13 in New York City
You may also be interested in...
GSK’s Garnier Touts “Progressive Blockbuster” As Model For Future Drugs
One way to handle an increasingly cautious FDA would be to take a different tack on development - pursuing "progressive blockbusters" that are approved on a population-by-population basis to prove the drugs are safe in different patient types rather than trying to make a traditional blockbuster big splash, according to GlaxoSmithKline CEO JP Garnier
GSK’s Garnier Touts “Progressive Blockbuster” As Model For Future Drugs
One way to handle an increasingly cautious FDA would be to take a different tack on development - pursuing "progressive blockbusters" that are approved on a population-by-population basis to prove the drugs are safe in different patient types rather than trying to make a traditional blockbuster big splash, according to GlaxoSmithKline CEO JP Garnier
Alzheimer’s Biomarker Data Ready For Release; Analyses Pose Next Challenge
Biomarker data for Alzheimer's disease will be publicized early this year, one of a number of government and private efforts aimed at pushing research forward in 2008